Takeda's TAK-360 Trial for Narcolepsy Type 1 Underway
Takeda is conducting a clinical trial to evaluate the safety and tolerability of TAK-360 in adults with Narcolepsy Type 1.
Phase III
Neurology / Sleep Disorders
Status
Active
Sponsor
Takeda
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing clinical trial of TAK-360 by Takeda represents a significant opportunity to enhance its portfolio in the niche market of narcolepsy treatment. Successful outcomes could position Takeda favorably against competitors and expand treatment options for patients with Narcolepsy Type 1.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include participant enrollment rates and interim results on safety and tolerability.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.